Maridebart cafraglutide versus placebo for adults with obstructive sleep apnea who are overweight or obese and not using PAP
Official title: A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure Therapy and Living With Overweight or Obesity (MARITIME-OSA-2)
Run by Amgen · NCT07226765 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study will test whether maridebart cafraglutide helps adults with obstructive sleep apnea who are overweight or obese and not using PAP therapy, compared with placebo over 52 weeks.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 99 Years |
| Sex | All |
| Enrollment | 250 (estimated) |
| Sponsor | Amgen Industry-sponsored |
| Locations | 42 sites (Northridge, California and 41 other locations) |
| Trial ID | NCT07226765 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with moderate-to-severe OSA (AHI ≥15) who have BMI ≥27 kg/m2, have tried weight loss, and are not using or planning to use PAP therapy are the intended participants.
✕Probably not a fit
People with predominant central apnea (≥50% central events), Cheyne–Stokes respiration, active PAP or oral appliance treatment, prior or planned upper airway surgery, or significant craniofacial abnormalities are unlikely to benefit from this study treatment.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a Phase 3, randomized, placebo-controlled trial comparing maridebart cafraglutide to placebo over 52 weeks in adults with obstructive sleep apnea who are not on PAP therapy. Eligible participants must have an apnea–hypopnea index (AHI) ≥15 on polysomnography and a BMI ≥27 kg/m2, with a history of at least one unsuccessful weight-loss attempt. Participants are randomized to receive maridebart cafraglutide or matching placebo and are monitored periodically for changes in OSA severity, body weight, and safety outcomes. Study visits and testing (including baseline and follow-up PSG) occur at clinical sites in California and Florida.
Why it matters
Potential benefit: If successful, the drug could reduce OSA severity and symptoms by promoting weight loss and airway improvement, offering a non‑PAP treatment option for patients unwilling or unable to use PAP.
How similar studies have gone: Other weight-loss drugs, particularly GLP-1 receptor agonists, have produced significant weight loss and modest improvements in OSA in smaller studies, but large phase 3 results specifically targeting OSA remain limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participants must have an AHI of 15 or higher on polysomnography (PSG) at Day 1 before randomization. * Body Mass Index (BMI) of 27 kg/m\^2 or more at the time of screening. * History of at least one unsuccessful attempt at weight loss through diet and exercise. * Participants must not have used PAP therapy for at least 4 weeks before screening, are unwilling/unable to use PAP, and do not plan to use PAP therapy during the study. Exclusion Criteria: * Individuals who have had any previous or planned upper airway surgery for sleep apnea or major ear, nose, or throat surgery. * Those with significant craniofacial abnormalities that may affect breathing at screening. * Participants diagnosed with Central Apnea with a percentage of central apneas/hypopneas of 50% or more, or those diagnosed with Cheyne Stokes Respiration. * Active device treatment of OSA (eg, PAP, oral appliances), or other treatments, that in the opinion of the investigator, may interfere with study outcomes, unless willing to stop treatment at screening and throughout the study. * Individuals with respiratory diseases like obesity hypoventilation syndrome or daytime hypercapnia, neuromuscular diseases or other conditions that could interfere with the trial results, according to the investigator's opinion.
Where it's running
-
Valley Clinical Trials
Northridge, California, United States Recruiting -
Peninsula Research Associates
Rolling Hills Estates, California, United States Recruiting -
Teradan Clinical Trials
Brandon, Florida, United States Recruiting -
Destiny Research Center
Palmetto Bay, Florida, United States Recruiting -
Clinical Research Center Of Florida
Pompano Beach, Florida, United States Recruiting -
NeuroTrials Research
Atlanta, Georgia, United States Recruiting
Show 36 more locations
-
Basil Clinical
Laurelton, New York, United States Recruiting -
Monroe Biomedical Research
Monroe, North Carolina, United States Recruiting -
CTI Clinical Research Center
Cincinnati, Ohio, United States Recruiting -
FutureSearch Trials of Neurology
Austin, Texas, United States Recruiting -
Epic Medical Research - DeSoto
DeSoto, Texas, United States Recruiting -
Sleep Therapy & Research Center
San Antonio, Texas, United States Recruiting -
Northwest Clinical Research Center
Bellevue, Washington, United States Recruiting -
Woolcock Institute of Medical Research
Macquarie Park, New South Wales, Australia Recruiting -
Royal Brisbane and Womens Hospital
Herston, Queensland, Australia Recruiting -
Monash Medical Centre
Clayton, Victoria, Australia Recruiting -
Nucleo de Pesquisa do Rio Grande do Sul
Porto Alegre, Rio Grande do Sul, Brazil Recruiting -
CPQuali Pesquisa Clinica Ltda
São Paulo, São Paulo, Brazil Recruiting -
Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo Hcfmusp
São Paulo, São Paulo, Brazil Recruiting -
CaRe Clinic
Calgary, Alberta, Canada Recruiting -
Aggarwal and Associates Ltd
Brampton, Ontario, Canada Recruiting -
Wharton Medical Clinic
Hamilton, Ontario, Canada Recruiting -
Nemocnice Rudolfa a Stefanie Benesov as
Benesov U Prahy, Czechia Recruiting -
Fakultni nemocnice Brno
Brno, Czechia Recruiting -
Cerebrovaskularni poradna sro
Ostrava - Poruba, Czechia Recruiting -
Advanced Sleep Research
Berlin, Germany Recruiting -
InnoDiab Forschung
Essen, Germany Recruiting -
Diabeteszentrum Hamburg West
Hamburg, Germany Recruiting -
Siteworks - Zentrum fuer klinische Studien Hannover
Hanover, Germany Recruiting -
Siteworks - Zentrum fuer klinische Studien Karlsruhe
Karlsruhe, Germany Recruiting -
Red-Institut GmbH
Oldenburg, Germany Recruiting -
Saiseikai Futsukaichi Hospital
Chikushino-shi, Fukuoka, Japan Recruiting -
Fukuoka University Hospital
Fukuoka, Fukuoka, Japan Recruiting -
Sleep and Mental Clinic-Kitahiroshima
Kitahiroshima-shi, Hokkaido, Japan Recruiting -
Kuwamizu Hospital
Kumamoto, Kumamoto, Japan Recruiting -
Nakamura Clinic
Urasoe-shi, Okinawa, Japan Recruiting -
Gokeikai Osaka Kaisei Hospital
Osaka, Osaka, Japan Recruiting -
Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut Badawczy
Warsaw, Poland Recruiting -
Centro Medico Teknon
Barcelona, Catalonia, Spain Recruiting -
Hospital Universitari Vall d Hebron
Barcelona, Catalonia, Spain Recruiting -
Hospital Medico Quirurgico San Rafael
A Coruña, Galicia, Spain Recruiting -
Hospital Universitario 12 de Octubre
Madrid, Spain Recruiting
Study contacts
- Study coordinator: Amgen Call Center
- Email: medinfo@amgen.com
- Phone: 866-572-6436
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Multimodal Deep Learning to Predict Sleep Apnea Severity from SpO2 and Ballistocardiography
Researchers are testing a smart-mattress-based method that uses SpO2 and ballistocardiography data to predict sleep apnea severity in adults undergoing overnight sleep study.
-
Nightly wearable monitoring with at-home submental electrical stimulation for sleep apnea
This pilot test checks whether wearing a ring sensor at night and doing a 4-week at-home submental electrical stimulation is feasible for adults with obstructive sleep apnea and looks at changes in sleep metrics.
-
Functional capacity and muscle function in adults with obstructive sleep apnea
This study tests how obstructive sleep apnea affects respiratory and peripheral muscle strength, endurance, and upper‑extremity function compared with healthy adults.
-
Transcutaneous Electrical Stimulation for Obstructive Sleep Apnea
This study tests whether applying gentle electrical stimulation to the throat muscles at night can reduce sleep apnea severity in adults with obstructive sleep apnea.
-
Physical activity habits and sleep/ breathing in obstructive sleep apnea
This study tests whether daily physical activity habits affect sleep quality and breathing measurements in people with obstructive sleep apnea who are on CPAP therapy.
-
CES-EES score and a wearable ring for diagnosing obstructive sleep apnea
This study tests whether the CES-EES clinical score and the Belun Ring wearable can accurately diagnose obstructive sleep apnea without in-lab polysomnography in adults referred for suspected OSA.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.